SuperworthKrystal Biotech profit margin KRYS
Gross, operating and net profit as a share of revenue over the last twelve months, from 2023.
- Net margin, 12 months
- 54.8%
- Operating margin, 12 months
- 44.9%
- Net margin on a year earlier
- +14.0 pts
- Peer median
- 22.9%
Over the twelve months to Jun 30, 2026, Krystal Biotech kept 54.8% of its revenue as net profit, with an operating margin of 44.9% and a gross margin of 94.6%.
The median for 10 biotech stocks of a similar size is 22.9%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 52.6% | 41.5% | 94.1% |
| FY2024 | 30.7% | 22.6% | 93.1% |
| FY2023 | 21.6% | n/a | 93.9% |
| FY2022 | n/a | n/a | n/a |
| FY2021 | n/a | n/a | n/a |
| FY2020 | n/a | n/a | n/a |
| FY2019 | n/a | n/a | n/a |
| FY2018 | n/a | n/a | n/a |
| FY2017 | n/a | n/a | n/a |
| FY2016 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 54.8% | +14.0 pts | 44.9% | |
| Q1 FY26 | 53.9% | +16.7 pts | 42.8% | |
| Q4 FY25 | 52.6% | +21.9 pts | 41.5% | |
| Q3 FY25 | 53.3% | +31.6 pts | 42.4% | |
| Q2 FY25 | 40.8% | −22.9 pts | 38.8% | |
| Q1 FY25 | 37.2% | −22.4 pts | 32.6% | |
| Q4 FY24 | 30.7% | +9.1 pts | 22.6% | |
| Q3 FY24 | 21.7% | n/a | 11.4% | |
| Q2 FY24 | 63.7% | n/a | −12.6% | |
| Q1 FY24 | 59.6% | n/a | −70.4% | |
| Q4 FY23 | 21.6% | n/a | n/a | |
| Q3 FY23 | n/a | n/a | n/a |
Against its peers
Companies in Biotechnology nearest Krystal Biotech's size, closest first, today.
| Company | Profit margin |
|---|---|
| KRYSKrystal Biotech | 54.8% |
| RGENRepligen | 5.3% |
| TECHBIO-TECHNE | 15.0% |
| HALOHalozyme Therapeutics | 24.9% |
| NBIXNeurocrine Biosciences | 20.9% |
| EXELExelixis | 35.3% |
| INCYIncyte | 27.7% |
| UTHRUnited Therapeutics | 41.6% |
| ALNYAlnylam Pharmaceuticals | 16.8% |
| ADMAAdma Biologics | 33.0% |
| VCELVericel | 7.9% |
| Peer median | 22.9% |
Where Krystal Biotech ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Krystal Biotech
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.